Turning a molecule into a medicine

The development of indacaterol as a novel once-daily bronchodilator treatment for patients with copd

Lorraine Murphy, Stephen Israel Rennard, James Donohue, Mathieu Molimard, Ronald Dahl, Kai Michael Beeh, Juergen Dederichs, Hans Jürgen Fülle, Mark Higgins, David Young

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Indacaterol is the first once-daily, long-acting β2-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β2-adrenergic agonist with a fast onset and long duration of action, enabling once-daily dosing with an acceptable safety profile. Early preclinical studies with indacaterol demonstrated these characteristics, and this promising molecule was taken into clinical development, originally for asthma treatment. Subsequent safety concerns over LABA monotherapy in patients with asthma redirected indacaterol's development to centre on COPD, where a good evidence base and guideline recommendations for bronchodilator monotherapy existed. Clinical development was initially complicated by different inhaler devices and differing doses of indacaterol. Using a phase III innovative adaptive-design clinical trial (INHANCE), indacaterol 150 and 300 μg once-daily doses were selected to be taken forward into the phase III INERGIZE programme. This programme delivered placebo-controlled and active-comparator data, including comparisons with formoterol, tiotropium and salmeterol/fluticasone, as well as the use of indacaterol in combination with tiotropium. Together, these studies provided a comprehensive assessment of the benefit-risk profile of indacaterol, allowing for regulatory submission. Indacaterol was first approved at once-daily doses of 150 and 300 μg in the European Union in 2009, followed by 150 μg in Japan (2011) and China (2012), and 75 μg in the United States (2011). To date, indacaterol is approved and marketed in more than 100 countries worldwide for once-daily maintenance treatment of COPD.

Original languageEnglish (US)
Pages (from-to)1635-1657
Number of pages23
JournalDrugs
Volume74
Issue number14
DOIs
StatePublished - Sep 12 2014

Fingerprint

Bronchodilator Agents
Medicine
Chronic Obstructive Pulmonary Disease
Therapeutics
Adrenergic Agonists
Asthma
indacaterol
Safety
Nebulizers and Vaporizers
Drug Design
European Union
China
Japan
Placebos
Clinical Trials
Guidelines
Equipment and Supplies

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Murphy, L., Rennard, S. I., Donohue, J., Molimard, M., Dahl, R., Beeh, K. M., ... Young, D. (2014). Turning a molecule into a medicine: The development of indacaterol as a novel once-daily bronchodilator treatment for patients with copd. Drugs, 74(14), 1635-1657. https://doi.org/10.1007/s40265-014-0284-7

Turning a molecule into a medicine : The development of indacaterol as a novel once-daily bronchodilator treatment for patients with copd. / Murphy, Lorraine; Rennard, Stephen Israel; Donohue, James; Molimard, Mathieu; Dahl, Ronald; Beeh, Kai Michael; Dederichs, Juergen; Fülle, Hans Jürgen; Higgins, Mark; Young, David.

In: Drugs, Vol. 74, No. 14, 12.09.2014, p. 1635-1657.

Research output: Contribution to journalArticle

Murphy, L, Rennard, SI, Donohue, J, Molimard, M, Dahl, R, Beeh, KM, Dederichs, J, Fülle, HJ, Higgins, M & Young, D 2014, 'Turning a molecule into a medicine: The development of indacaterol as a novel once-daily bronchodilator treatment for patients with copd', Drugs, vol. 74, no. 14, pp. 1635-1657. https://doi.org/10.1007/s40265-014-0284-7
Murphy, Lorraine ; Rennard, Stephen Israel ; Donohue, James ; Molimard, Mathieu ; Dahl, Ronald ; Beeh, Kai Michael ; Dederichs, Juergen ; Fülle, Hans Jürgen ; Higgins, Mark ; Young, David. / Turning a molecule into a medicine : The development of indacaterol as a novel once-daily bronchodilator treatment for patients with copd. In: Drugs. 2014 ; Vol. 74, No. 14. pp. 1635-1657.
@article{2dbcb3123fe645688021327f1628ec86,
title = "Turning a molecule into a medicine: The development of indacaterol as a novel once-daily bronchodilator treatment for patients with copd",
abstract = "Indacaterol is the first once-daily, long-acting β2-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β2-adrenergic agonist with a fast onset and long duration of action, enabling once-daily dosing with an acceptable safety profile. Early preclinical studies with indacaterol demonstrated these characteristics, and this promising molecule was taken into clinical development, originally for asthma treatment. Subsequent safety concerns over LABA monotherapy in patients with asthma redirected indacaterol's development to centre on COPD, where a good evidence base and guideline recommendations for bronchodilator monotherapy existed. Clinical development was initially complicated by different inhaler devices and differing doses of indacaterol. Using a phase III innovative adaptive-design clinical trial (INHANCE), indacaterol 150 and 300 μg once-daily doses were selected to be taken forward into the phase III INERGIZE programme. This programme delivered placebo-controlled and active-comparator data, including comparisons with formoterol, tiotropium and salmeterol/fluticasone, as well as the use of indacaterol in combination with tiotropium. Together, these studies provided a comprehensive assessment of the benefit-risk profile of indacaterol, allowing for regulatory submission. Indacaterol was first approved at once-daily doses of 150 and 300 μg in the European Union in 2009, followed by 150 μg in Japan (2011) and China (2012), and 75 μg in the United States (2011). To date, indacaterol is approved and marketed in more than 100 countries worldwide for once-daily maintenance treatment of COPD.",
author = "Lorraine Murphy and Rennard, {Stephen Israel} and James Donohue and Mathieu Molimard and Ronald Dahl and Beeh, {Kai Michael} and Juergen Dederichs and F{\"u}lle, {Hans J{\"u}rgen} and Mark Higgins and David Young",
year = "2014",
month = "9",
day = "12",
doi = "10.1007/s40265-014-0284-7",
language = "English (US)",
volume = "74",
pages = "1635--1657",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "14",

}

TY - JOUR

T1 - Turning a molecule into a medicine

T2 - The development of indacaterol as a novel once-daily bronchodilator treatment for patients with copd

AU - Murphy, Lorraine

AU - Rennard, Stephen Israel

AU - Donohue, James

AU - Molimard, Mathieu

AU - Dahl, Ronald

AU - Beeh, Kai Michael

AU - Dederichs, Juergen

AU - Fülle, Hans Jürgen

AU - Higgins, Mark

AU - Young, David

PY - 2014/9/12

Y1 - 2014/9/12

N2 - Indacaterol is the first once-daily, long-acting β2-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β2-adrenergic agonist with a fast onset and long duration of action, enabling once-daily dosing with an acceptable safety profile. Early preclinical studies with indacaterol demonstrated these characteristics, and this promising molecule was taken into clinical development, originally for asthma treatment. Subsequent safety concerns over LABA monotherapy in patients with asthma redirected indacaterol's development to centre on COPD, where a good evidence base and guideline recommendations for bronchodilator monotherapy existed. Clinical development was initially complicated by different inhaler devices and differing doses of indacaterol. Using a phase III innovative adaptive-design clinical trial (INHANCE), indacaterol 150 and 300 μg once-daily doses were selected to be taken forward into the phase III INERGIZE programme. This programme delivered placebo-controlled and active-comparator data, including comparisons with formoterol, tiotropium and salmeterol/fluticasone, as well as the use of indacaterol in combination with tiotropium. Together, these studies provided a comprehensive assessment of the benefit-risk profile of indacaterol, allowing for regulatory submission. Indacaterol was first approved at once-daily doses of 150 and 300 μg in the European Union in 2009, followed by 150 μg in Japan (2011) and China (2012), and 75 μg in the United States (2011). To date, indacaterol is approved and marketed in more than 100 countries worldwide for once-daily maintenance treatment of COPD.

AB - Indacaterol is the first once-daily, long-acting β2-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β2-adrenergic agonist with a fast onset and long duration of action, enabling once-daily dosing with an acceptable safety profile. Early preclinical studies with indacaterol demonstrated these characteristics, and this promising molecule was taken into clinical development, originally for asthma treatment. Subsequent safety concerns over LABA monotherapy in patients with asthma redirected indacaterol's development to centre on COPD, where a good evidence base and guideline recommendations for bronchodilator monotherapy existed. Clinical development was initially complicated by different inhaler devices and differing doses of indacaterol. Using a phase III innovative adaptive-design clinical trial (INHANCE), indacaterol 150 and 300 μg once-daily doses were selected to be taken forward into the phase III INERGIZE programme. This programme delivered placebo-controlled and active-comparator data, including comparisons with formoterol, tiotropium and salmeterol/fluticasone, as well as the use of indacaterol in combination with tiotropium. Together, these studies provided a comprehensive assessment of the benefit-risk profile of indacaterol, allowing for regulatory submission. Indacaterol was first approved at once-daily doses of 150 and 300 μg in the European Union in 2009, followed by 150 μg in Japan (2011) and China (2012), and 75 μg in the United States (2011). To date, indacaterol is approved and marketed in more than 100 countries worldwide for once-daily maintenance treatment of COPD.

UR - http://www.scopus.com/inward/record.url?scp=84910668475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910668475&partnerID=8YFLogxK

U2 - 10.1007/s40265-014-0284-7

DO - 10.1007/s40265-014-0284-7

M3 - Article

VL - 74

SP - 1635

EP - 1657

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 14

ER -